TWO · 6586.TWO
CHO Pharma, Inc.
NT$100.00-NT$3.50 (-3.38%)
CHO Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.66% below the high.
Loading market information…
TAI · 4746.TW · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Formosa Laboratories, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.82% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Formosa Laboratories, Inc.’s forward annual dividend is NT$3.00 per share, paid annual. The forward yield is 6.53% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Formosa Laboratories, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of NT$0.01. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Formosa Laboratories, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Formosa Laboratories, Inc., together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. It offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomodulators, respiratory agents, cholesterol and phosphate binders, UV filter, iron deficiency anemia (IDA), CNS agents, MRI enhancing agents, steroids, antibiotics, and other areas; and injectables in the areas of IDA, MRI agents, oncology, and others. The company also provides contract development and manufacturing services, including recrystallization, filtration, dialysis, column purification, distillation, spray drying, and micronization; injectable manufacturing and secondary packaging, labeling, and serialization services; custom fermentation services; and peptide synthesis services. In addition, it offers antibody-drug conjugates services comprising antibody development and manufacture; peptide and polymer drug conjugation; linker-payload design, synthesis, and manufacturing; bio-conjugation and purification; cytotoxic liquid-filled and lyophilized product from pre-formulation studies to manufacture; and regulatory support. Further, the company is involved in chemical trading and investment activities. Formosa Laboratories, Inc. was incorporated in 1985 and is headquartered in Taoyuan City, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| NT$1.14B+14.37% vs estimate |
| Q4 2024 | Mar 12, 2025 | -NT$0.44-120.37% vs estimate | NT$1.35B+10.6% vs estimate |
|---|
| Q3 2024 | Nov 14, 2024 | NT$0.19-86.81% vs estimate | NT$1.03B-0.01% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$100.00-NT$3.50 (-3.38%)
CHO Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.66% below the high.
NT$56.70-NT$0.20 (-0.35%)
Standard Chem & Pharm Co. Ltd.’s quoted price sits in the upper half of its reported 52-week range, 6.36% below the high.
NT$17.20-NT$0.30 (-1.71%)
Adimmune Corporation’s quoted price sits in the lower half of its reported 52-week range, 23.56% below the high.
NT$51.00-NT$0.60 (-1.16%)
SCI Pharmtech, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.98% below the high.
NT$8.37-NT$0.31 (-3.57%)
TaiGen Biopharmaceuticals Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 48.96% below the high.
NT$23.30-NT$0.20 (-0.85%)
Orient Pharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 21.28% below the high.
NT$142.00-NT$3.00 (-2.07%)
Delta Asia International Corporation’s quoted price sits in the lower half of its reported 52-week range, 29.0% below the high.
NT$22.25-NT$0.25 (-1.11%)
Mycenax Biotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.86% below the high.
